Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH 77 Cash-to-Debt is 0.06 as of Jun. 2026, which is 14% below its 10-year median of 0.07. GuruFocus rates XSWX:ZBH with a GF Score™ of 77/100 and a GF Value™ of CHF101.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks worse than 94.54% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zimmer Biomet Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.06.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Zimmer Biomet Holdingscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Zimmer Biomet Holdings's Cash-to-Debt or its related term are showing as below:
XSWX:ZBH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.25
Current: 0.06
During the past 13 years, Zimmer Biomet Holdings's highest Cash to Debt Ratio was 0.25. The lowest was 0.04. And the median was 0.07.
XSWX:ZBH's Cash-to-Debt is ranked worse than 94.54% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs XSWX:ZBH: 0.06
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Zimmer Biomet Holdings Cash-to-Debt Related Terms
Zimmer Biomet Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:ZBH vs STE, PEN, GMED: Cash-to-Debt Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a Cash-to-Debt of 0.06 as of Jun. 2026. This is 14% below median its historical median of 0.07. Over the past decade, Zimmer Biomet Holdings' Cash-to-Debt has ranged from 0.04 to 0.25. According to the industry distribution chart, Zimmer Biomet Holdings ranks #796 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 94.5%.
Is Zimmer Biomet Holdings' Cash-to-Debt too high?
Zimmer Biomet Holdings' current Cash-to-Debt of 0.06 is 14% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.25. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Zimmer Biomet Holdings' value of 0.06 is 96.3% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #796 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Cash-to-Debt compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #796 out of 842 companies for Cash-to-Debt. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Zimmer Biomet Holdings' value of 0.06 is 96.3% below this benchmark. Historically, Zimmer Biomet Holdings' own Cash-to-Debt has ranged from 0.04 to 0.25 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 1.64, Zimmer Biomet Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Cash-to-Debt of 0.06 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Cash-to-Debt is 0.06, which is 14% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF101.56, compared to a current price of CHF75.50 — trading 25.7% below its estimated fair value. The current Cash-to-Debt is 0.06, which is 14% below median its 10-year median of 0.07 and 96.3% below the Medical Devices & Instruments industry median of 1.64. Zimmer Biomet Holdings' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Cash-to-Debt is 0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF75.50 is trading 25.7% below its estimated GF Value™ of CHF101.56.
GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.
Key valuation signals for XSWX:ZBH:
Cash-to-Debt: 0.06 (14% below median its 10-year median of 0.07)
GF Value™: CHF101.56 vs. price of CHF75.50 (25.7% below fair value)
Industry Position: 96.3% below the Medical Devices & Instruments median (#796 of 842)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
77GF Score
Get the complete analysis for XSWX:ZBH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
